Strong Full Year Result

Strong Full Year Result

Melbourne, Australia — 12/08/2015

Double digit growth in albumin and specialty products
CSL becomes No.2 global influenza vaccines manufacturer
New Privigen® facility completed
Board to consider further share buyback


CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,379 million for the full year ended 30 June 2015, up 6% on a reported basis when compared to the prior comparable period (PCP). NPAT grew 10% on a constant currency1 basis, after adjusting for the one-off costs2 associated with the acquisition of the Novartis influenza vaccine business.

Financial Highlights
  • Sales US$5,459 million, up 2% on PCP
    o Up 7% at constant currency1 
  • EBIT US$1,758 million, up 7% on PCP
    o Up 12% at constant currency & after adjusting for acquisition costs2
  • NPAT US$1,379 million, up 6% on PCP
    o Up 10% at constant currency & after adjusting for acquisition costs
  • Earnings per share US$2.92, up 8% on PCP
    o Up 13% at constant currency & after adjusting for acquisition costs
  • Research and development investment was US$463 million
  • Final dividend3 increased 10% to US$0.66 per share, unfranked for Australian tax purposes, payable on 2 October 2015
    o Converted to Australian currency, the final dividend increased to approximately A$0.90 per share, up 39% on PCP.

Operational Highlights
  • Acquisition of Novartis‘ global influenza vaccine business
  • bioCSL business turnaround
  • Hizentra® (subcutaneous immunoglobulin) - European Medical Agency & U.S. Food and Drug Administration (FDA) approved flexible dosing
  • CSL 654 (rIX-FP) - license application submitted to U.S. and European regulators
  • CSL 627 (rFVIII-SingleChain) – license application submitted to U.S. FDA
  • CSL 112 (rHDL) – global phase IIb clinical trial recruiting rapidly
  • Major capital projects completed

Capital Management

  • A$950 million share buyback completed
  • New buyback4 foreshadowed
  • New private placement foreshadowed


Download this release:
 
PDF icon CSL Full Year results announcement for 2015 (0.30Mb)

Additional resources:
Details about CSL's results are included in the company's 4E statement, investor presentation slides and webcast. More ...

For further information, please contact:
     

Investors:
  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: mark.dehring@csl.com.au
Media:
  Sharon McHale
  Head of Public Affairs
  CSL Limited
  Mobile: +614 0997 8314
  Email: sharon.mchale@csl.com.au




1 Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note for further detail. 
2 One-off costs totalling $22 million connected with the acquisition of the Novartis influenza vaccine business 
3 For shareholders with an Australian registered address, dividends will be paid in A$ at an amount of A$0.899910 per share (at an exchange rate of A$1.3635/US$1.00), and for shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$1.006104 per share (at an exchange rate of NZ$1.5244/US$1.00). The exchange rates used are fixed at the date of dividend determination. All other shareholders will be paid in US$.
4 CSL reserves the right to suspend or terminate buy-backs at any time.

 

© 2016 CSL Limited